Although mutation in drug target genes is one of the major causes for drug resistance in many types of cancer, mutations in actionable molecules have been uncommon in HCC, for example, EGFR activating mutations have been reported to occur in 0∼1% of HCC [31], [32] and Raf mutations have never been described in HCC [33]. Here, EGFR is linked to hepatocellular carcinoma.